Unique ID issued by UMIN | UMIN000025187 |
---|---|
Receipt number | R000028684 |
Scientific Title | Phase III study of watchful waiting versus rituximab as first-line treatment in patients with low tumor burden of advanced stage follicular lymphoma(JCOG1411, FLORA study) |
Date of disclosure of the study information | 2016/12/08 |
Last modified on | 2023/10/11 18:54:24 |
Phase III study of watchful waiting versus rituximab as first-line treatment in patients with low tumor burden of advanced stage follicular lymphoma(JCOG1411, FLORA study)
Phase III study of watchful waiting versus rituximab as first-line treatment in patients with low tumor burden of advanced stage follicular lymphoma(JCOG1411, FLORA study)
Phase III study of watchful waiting versus rituximab as first-line treatment in patients with low tumor burden of advanced stage follicular lymphoma(JCOG1411, FLORA study)
Phase III study of watchful waiting versus rituximab as first-line treatment in patients with low tumor burden of advanced stage follicular lymphoma(JCOG1411, FLORA study)
Japan |
Follicular lymphoma
Hematology and clinical oncology |
Malignancy
NO
To confirm the efficacy of rituximab as first-line treatment versus watchful waiting in patients with low tumor burden of advanced stage follicular lymphoma
Efficacy
Confirmatory
Phase III
Event-free survival
cytotoxic therapy-free survival, histological transformation-free survival, overall survival, progression-free survival, response proportion, adverse events, severe adverse events.
Interventional
Parallel
Randomized
Individual
Open -no one is blinded
Active
NO
YES
Institution is considered as adjustment factor in dynamic allocation.
NO
Central registration
2
Treatment
Medicine |
A: Watchful waiting. When at least one of the following (i) to (iii) is fulfilled, 1 cycle of rituximab at 375 mg/m2 on day1, 8, 15, and 22 is administered. (i) more than 5 cm and less than 7 cm in the maximum tumor diameter (ii) three nodal sites of 3 cm (iii) moderate pleural and peritoneal effusion.
B: Rituximab as first-line treatment. 1 cycle of rituximab at 375 mg/m2 on day1, 8, 15, and 22. When at least one of the following (i) to (iii) is fulfilled, 1 cycle of rituximab is administered. (i) more than 5cm and less than 7cm in the maximum tumor diameter (ii) three nodal sites of 3 cm (iii) moderate pleural and peritoneal effusion.
20 | years-old | <= |
80 | years-old | >= |
Male and Female
1) Follicular lymphoma (Grade1, 2 and 3A) with CD20 positive.
2) Ann Arbor CS III and IV diagnosed by CT and bone marrow examination within 56 days before entry
3) The following (i) to (vi) are fulfilled by physical findings and CT within 56 days before entry
(i) Largest nodal or extra nodal mass less than 5cm
(ii) Two or less nodal sites with a diameter of 3cm or more
(iii) The absence of B symptoms
(iv) Spleen size is less than 16cm by CT
(v) No significant serous effusions
(vi) No critical organ compression
4) Aged 20 to 80 years old
5) ECOG performance status (PS) of 0 or 1
6) Bidimensionally measurable disease >1.5cm in a single dimention by CT
7) No prior chemotherapy, radiotherapy, interferon-alfa, or antibody therapy
8) Patients with sufficient organ functions
9) Written informed consent
1. Synchronous double or multiple cancer or metachronous double or multiple cancer with progression free period less than 5 years.
2. Infectious disease requiring systemic treatment.
3. Female during pregnancy, within 28 days of postparturition, or during lactation and male expecting partner's pregnancy.
4. Severe psychological disorder.
5. Receiving continuous systemic corticosteroid or immunosuppressant treatment.
6. Insulin-dependent or uncontrollable diabetes mellitus
7. Uncontrollable hypertension
8. Unstable angina pectoris, or history of myocardial infarction within six months.
9. HBs-Ag positive or HCV-Ab positive
10. HBs-Ab positive or HBc-Ab positive with HBV DNA levels of 2.1 log copies/mL or more
11. Positive HIV antibody
12. Uncontrollable glaucoma
290
1st name | Ishizawa |
Middle name | |
Last name | Kenichi |
Yamagata University Faculty of Medicine
Department of Hematology and Cell Therapy
990-9585
2-2-2 Iidanishi, Yamagata city, Yamagata Prefecture, 990-9585 Japan
023-628-5516
kishizaw@med.id.yamagata-u.ac.jp
1st name | Fukuhara |
Middle name | |
Last name | Noriko |
JCOG1411Coordinating Office
Department of Hematology and Rheumatology, Tohoku University Graduate School of Medicine
980-8574
1-1 Seiryo-machi, Aoba-ku, Sendai, Miyagi Prefecture, 980-8574 Japan
022-717-7165
http://www.jcog.jp/
JCOG_sir@ml.jcog.jp
Japan Clinical Oncology Group (JCOG)
National Cancer Center
Other
Japan
National Cancer Center Institutional Review Board
5-1-1 Tsukiji, Chuo-ku, Tokyo
03-3542-2511
NCC_IRBoffice@ml.res.ncc.go.jp
NO
国立病院機構北海道がんセンター(北海道)
札幌北楡病院(北海道)
東北大学病院(宮城県)
秋田大学医学部(秋田県)
山形大学医学部(山形県)
群馬大学医学部附属病院(群馬県)
埼玉県立がんセンター(埼玉県)
埼玉医科大学総合医療センター(埼玉県)
国立がん研究センター東病院(千葉県)
千葉県がんセンター(千葉県)
国立がん研究センター中央病院(東京都)
杏林大学医学部(東京都)
東京慈恵会医科大学附属病院(東京都)
東京慈恵会医科大学第三病院(東京都)
順天堂大学医学部附属順天堂医院(東京都)
NTT東日本関東病院(東京都)
東海大学医学部(神奈川県)
金沢医科大学(石川県)
福井大学医学部附属病院(福井県)
浜松医科大学(静岡県)
愛知県がんセンター中央病院(愛知県)
国立病院機構名古屋医療センター(愛知県)
名古屋大学医学部(愛知県)
名古屋市立大学病院(愛知県)
名古屋第二赤十字病院(愛知県)
愛知医科大学附属病院(愛知県)
豊田厚生病院(愛知県)
三重大学医学部(三重県)
滋賀県立成人病センター(滋賀県)
京都府立医科大学(京都府)
兵庫県立がんセンター(兵庫県)
岡山医療センター(岡山県)
広島大学病院(広島県)
国立病院機構四国がんセンター(愛媛県)
愛媛大学医学部附属病院(愛媛県)
国立病院機構九州がんセンター(福岡県)
福岡大学医学部(福岡県)
国立病院機構九州医療センター(福岡県)
産業医科大学(福岡県)
佐賀大学医学部(佐賀県)
国立病院機構長崎医療センター(長崎県)
佐世保市総合医療センター(長崎県)
長崎大学病院(長崎県)
日本赤十字社長崎原爆病院(長崎県)
熊本大学医学部(熊本県)
国立病院機構熊本医療センター(熊本県)
大分県立病院(大分県)
鹿児島大学医学部・歯学部附属病院(鹿児島県)
今村病院分院(鹿児島県)
琉球大学医学部附属病院(沖縄県)
2016 | Year | 12 | Month | 08 | Day |
Unpublished
No longer recruiting
2016 | Year | 10 | Month | 07 | Day |
2016 | Year | 11 | Month | 10 | Day |
2016 | Year | 12 | Month | 08 | Day |
2027 | Year | 12 | Month | 08 | Day |
2016 | Year | 12 | Month | 08 | Day |
2023 | Year | 10 | Month | 11 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000028684
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |